Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluad Quadrivalent
- Development stage
- Approved
- Lead developer
- CSL Seqirus
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
**Fluad Quadrivalent** is a seasonal, egg-derived, inactivated quadrivalent influenza surface-antigen vaccine formulated with the MF59C.1 squalene-based oil-in-water adjuvant. In the NCT05518500 FluVax3 longitudinal study, the intervention labeled **Flu Vaccine Year 2** was Fluad Quadrivalent administered during the 2023-2024 influenza season to adults aged 65 years and older. It is intended to induce protective immune responses against the included influenza A and B strains and prevent influenza disease.
- Brand names
- Fluad Quadrivalent
- Other names
- Flu Vaccine Year 2
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Fluad Quadrivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fluad Quadrivalent.